Brokerages predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will announce $680,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Infinity Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.50 million and the lowest estimate coming in at $200,000.00. Infinity Pharmaceuticals posted sales of $22.00 million in the same quarter last year, which would suggest a negative year over year growth rate of 96.9%. The company is expected to announce its next earnings results on Monday, November 4th.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year sales of $3.73 million for the current financial year, with estimates ranging from $2.00 million to $7.00 million. For the next financial year, analysts expect that the business will post sales of $1.52 million, with estimates ranging from $800,000.00 to $2.23 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Tuesday, July 30th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Infinity Pharmaceuticals had a negative net margin of 77.80% and a negative return on equity of 42.16%. The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $2.60 million.
A number of research firms recently issued reports on INFI. CIBC began coverage on shares of Infinity Pharmaceuticals in a report on Thursday, June 27th. They issued an “outperform” rating for the company. Oppenheimer began coverage on shares of Infinity Pharmaceuticals in a report on Thursday, June 27th. They issued an “outperform” rating and a $3.00 target price for the company. Finally, ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $2.67.
Infinity Pharmaceuticals stock traded up $0.02 during trading on Friday, reaching $1.22. The company had a trading volume of 44,397 shares, compared to its average volume of 63,728. Infinity Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $2.92. The stock’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.57. The firm has a market capitalization of $69.01 million, a price-to-earnings ratio of -6.10 and a beta of 1.79. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.93 and a current ratio of 7.93.
Institutional investors have recently added to or reduced their stakes in the stock. Community Bank N.A. grew its holdings in Infinity Pharmaceuticals by 71.4% in the first quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the period. Parametric Portfolio Associates LLC acquired a new position in Infinity Pharmaceuticals during the second quarter valued at approximately $76,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Infinity Pharmaceuticals by 54.2% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 15,908 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Infinity Pharmaceuticals by 73.6% during the fourth quarter. Bank of New York Mellon Corp now owns 72,256 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 30,622 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in Infinity Pharmaceuticals by 29.4% during the fourth quarter. Two Sigma Investments LP now owns 91,296 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 20,721 shares in the last quarter. Hedge funds and other institutional investors own 54.17% of the company’s stock.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Recommended Story: What do I need to know about analyst ratings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.